Research Study to Determine Sensitivity to Gentle Touch and Pressure During an Active Migraine Attack.

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

28 participants

Study Classification

OBSERVATIONAL

Study Start Date

2006-03-31

Study Completion Date

2008-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Cutaneous allodynia (pronounced q-tane-ee-us all-o-din-ee-a) is common in migraine. It is a heightened skin sensitivity during an active migraine attack. Migraine attacks in patients who experience allodynia are more difficult to treat. This study intends to collect and evaluate data on the phenomenon of allodynia in patients with episodic migraine during an actual attack. The results of this study may help clinicians better understand allodynia, thereby helping them diagnose and more effectively manage patients with migraine and allodynia.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Research Study to Examine Cutaneous Allodynia and Cluster Headache

NCT00329836

Cluster Headache

COMPLETED

A Study Examining the Use of a Migraine Medicine in the Treatment of Two Migraine Attacks in Patients Who Have Increased Skin Sensitivity

NCT00203268

Migraine

COMPLETED NA

A Research Study Examining Migranal and Skin Sensitivity in Subjects With Migraine

NCT00335777

Migraine

COMPLETED PHASE4

Defining the Sympathetic Skin Response of Migraineurs in the Facial Area

NCT03772860

Migraine Disorders

UNKNOWN

Interest of Auriculotherapy in Prophylaxis of Migraine and Headache in Patients With Migraines

NCT03036761

Headache, Migraine

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Migraine

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Episodic migraineurs

Eligible subjects with episodic migraine (with or without aura)

No intervention: We are testing for the presence of allodynia

Intervention Type OTHER

We are testing for the presence of abnormal sensation (allodynia) during a migraine attack.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

No intervention: We are testing for the presence of allodynia

We are testing for the presence of abnormal sensation (allodynia) during a migraine attack.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male and female patients aged 18-65, inclusive
* Diagnosis of episodic migraine with or without aura.
* Ability to read and understand an informed consent form and study procedures

Exclusion Criteria

* Patients with abnormal sensory findings on examination, or any known neurological disease that may affect skin sensation (peripheral neuropathy, multiple sclerosis, stroke, etc).
* Patients who suffer from headache (of any type) 15 or more days per month
* Patients who are cognitively impaired, as determined by investigator
* Patients with significant psychiatric disorder that may affect their understanding of the study protocol and/or their cooperation with the investigators.
* Patients who had taken any acute pain medication (e.g. triptans, ergots, NSAIDs, opioids, butalbital, acetaminophen) for any indication within 12 hours prior to allodynia testing.
* Patients with skin diseases that may cause abnormal skin sensation.
* Patients who had been treated with a nerve block in the 4 week period prior to allodynia testing Patients who had been treated with Botulinum neurotoxin within the 4 month period prior to allodynia testing

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No